Medication info

Bonthield (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
A colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with a single-use injection needle attached.
Packaging
3mL/prefilled syringe x 1
Approval status
Active

MFDS item code 201306428 · Approved 2013.03.22 · Insurance code 645304621

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as adjunctive supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is required. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. This drug is not recommended for patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min because clinical experience is insufficient. Older adults No dosage adjustment is required.
Child administration
Efficacy and safety have not been studied in children 18 years of age or younger.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medicine is used to treat osteoporosis that occurs in postmenopausal women. After menopause, women may experience a decrease in bone density due to a decrease in estrogen, and this drug helps maintain strong bones and reduce the risk of fractures. Therefore, it is effective in preventing fractures and improving bone health due to postmenopausal osteoporosis.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as adjunctive supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is required. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. This drug is not recommended for patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min because clinical experience is insufficient. Older adults No dosage adjustment is required.

Child administration

Efficacy and safety have not been studied in children 18 years of age or younger.

Precautions

This drug must be administered only by intravenous injection, and caution is required as incorrect injection near arteries or veins can cause tissue damage. It should not be administered to patients who have hypersensitivity to this drug or untreated hypocalcemia. This drug is used for the treatment of osteoporosis and has shown similar safety to placebo in most patients in clinical trials. However, some patients may experience gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation, as well as musculoskeletal adverse reactions such as musculoskeletal pain, arthralgia, and myalgia. Additionally, flu-like symptoms (joint pain, muscle pain, fever, chills, fatigue, etc.) may temporarily occur after injection, usually mild and resolve without treatment. Rarely, serious side effects such as hypersensitivity reactions, angioedema, urticaria, severe skin reactions, anaphylaxis, osteonecrosis, and atypical fractures have been reported. In particular, osteonecrosis of the jaw and external auditory canal may occur in patients using this drug, so it is important to have oral examinations and preventive dental treatments before administration. It is advisable to avoid excessive dental treatment during therapy. This drug may temporarily lower serum calcium levels, so any hypocalcemia and bone and mineral metabolism disorders must be treated before administration, along with sufficient intake of calcium and vitamin D. It may affect kidney function; therefore, patients with kidney disease or those taking medications affecting the kidneys require regular examinations and monitoring. The safety for pregnant and lactating women has not been established and it is recommended not to use it as reproductive toxicity was observed in animal studies. In case of overdose, renal and hepatic functions should be carefully monitored, and appropriate treatment should be administered if electrolyte imbalances such as hypocalcemia occur. This drug should not be mixed with calcium-containing solutions or other intravenous drugs, and must be diluted with normal saline or dextrose solution for administration. Keep out of reach of children, and safely dispose of used injection needles and syringes without reuse.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • dyspepsia
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • myalgia
  • influenza-like illness
Show 65 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reaction
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reaction
  • angioedema
  • facial swelling
  • edema
  • urticaria
  • uveitis
  • episcleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • exacerbation of asthma
  • Stevens-Johnson syndrome
  • erythema multiforme
  • vesicular dermatitis
  • atypical electronic fracture
  • intertrochanteric femoral fracture
  • myalgia
  • joint pain
  • dyspepsia
  • influenza-like illness
  • musculoskeletal pain
  • headache
  • gastritis
  • nausea
  • fatigue
  • dizziness
  • fever
  • hypothyroidism
  • peripheral neuropathy
  • hearing loss
  • dyspnea
  • skin peeling
  • multiple organ failure
  • death
  • dizziness
  • fracture
  • optic nerve atrophy
  • lower motor neuron lesions
  • tremor
  • gastrointestinal diseases
  • benign gastrointestinal neoplasm
  • toothache
  • hyperventilation
  • cough
  • laryngitis
  • vaginitis
  • menopausal symptoms
  • insomnia
  • anxiety
  • tinnitus
  • lipoma
  • ocular bleeding
  • heart failure
  • urination disorders
  • hematuria
  • sensory loss
  • acute kidney failure

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent air from entering and should be kept at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the drug's efficacy and prevents deterioration.

Appearance and packaging

Appearance

A colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with a single-use injection needle attached.

Package unit

3mL/prefilled syringe x 1

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.